Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Testing of Lung Cancers

21 Apr 2017

Abstract excerpt

Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28427247
DOI: 10.4132/jptm.2017.04.10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Testing of Lung CancersPMID 28427247Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.Semantic proximity Read ↗

Molecular Pathology of Lung Cancer.Semantic proximity Read ↗

Molecular Testing in Lung Cancer: Recommendations and Update.Semantic proximity Read ↗

The Molecular Pathology of Lung Cancer.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Molecular testing and personalized treatment of lung cancer.Semantic proximity Read ↗

Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Semantic proximity Read ↗

Current status of molecular diagnostics for lung cancerSemantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.